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Abstract
In humans, cytomegalovirus (CMV) is the most significant infectious cause of intrauterine infections that cause congenital
anomalies of the central nervous system. Currently, it is not known how this process is affected by the timing of infection
and the susceptibility of early-gestational-period cells. Embryonic stem (ES) cells are more resistant to CMV than most other
cell types, although the mechanism responsible for this resistance is not well understood. Using a plaque assay and
evaluation of immediate-early 1 mRNA and protein expression, we found that mouse ES cells were resistant to murine CMV
(MCMV) at the point of transcription. In ES cells infected with MCMV, treatment with forskolin and trichostatin A did not
confer full permissiveness to MCMV. In ES cultures infected with elongation factor-1a (EF-1a) promoter-green fluorescent
protein (GFP) recombinant MCMV at a multiplicity of infection of 10, less than 5% of cells were GFP-positive, despite the fact
that ES cells have relatively high EF-1a promoter activity. Quantitative PCR analysis of the MCMV genome showed that ES
cells allow approximately 20-fold less MCMV DNA to enter the nucleus than mouse embryonic fibroblasts (MEFs) do, and
that this inhibition occurs in a multi-step manner. In situ hybridization revealed that ES cell nuclei have significantly less
MCMV DNA than MEF nuclei. This appears to be facilitated by the fact that ES cells express less heparan sulfate, b1 integrin,
and vimentin, and have fewer nuclear pores, than MEF. This may reduce the ability of MCMV to attach to and enter through
the cellular membrane, translocate to the nucleus, and cross the nuclear membrane in pluripotent stem cells (ES/induced
pluripotent stem cells). The results presented here provide perspective on the relationship between CMV susceptibility and
cell differentiation.
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Introduction
In humans, cytomegalovirus (CMV), a member of the herpes
virus family, is the most significant infectious source of intrauterine
infections that cause congenital anomalies. Intrauterine infection
with human cytomegalovirus (HCMV) is thought to be responsible
for a variety of abnormalities, depending on the timing of fetal
infection, infectious route, and virulence of the virus [1].
Differential susceptibility of certain early embryonic cells to
HCMV infection may cause abnormal embryogenesis or organ-
ogenesis, resulting in central nervous system defects. Previous
studies have demonstrated altered susceptibility to CMV infection
among different cell types, including various types of stem/
progenitor cells [2,3,4,5,6,7]. This can cause abnormal embryo-
genesis and/or organogenesis, which, in turn, results in congenital
anomalies [8].
Studies of human subjects have obvious limitations, but CMVs
exhibit strict species specificity, and HCMV therefore cannot be
studied directly in any laboratory animal. Thus, general CMV
pathogenesis has been examined in mice, using murine CMV
(MCMV) [9,10], and in guinea pigs, using guinea pig CMV[11].
Interestingly, mouse embryos injected with MCMV-infected
blastocysts do not express viral genes, suggesting that they are
not susceptible to MCMV [12]. Further, mouse embryonic stem
(ES) cells are non-permissive to MCMV infection, and the
MCMV immediate-early (IE) promoter is not activated in ES
cells from transgenic mice [4]. Human NTera2/D1 embryonic
carcinoma cells (NT2) are a useful model in which to study the
regulatory mechanisms behind major immediate-early (MIE)
enhancer/promoter silencing during quiescent HCMV infection
[5,13,14]. This is because HCMV replication is prevented in
embryonic NT2 cells, where viral MIE gene expression is
blocked, but not in differentiated cells [5,13,15,16]. Trichostatin
A (TSA), an inhibitor of histone deacetylases, brings about MIE
enhancer/promoter reactivation in quiescently infected NT2
[17], independent of cellular differentiation [18]. Treatment with
TSA disrupts heterochromatin nucleation at the MIE enhancer/
promoter [18], a process akin to the chromatin disruption
that accompanies HCMV reactivation in endogenously-infected
dendritic cells [6]. Stimulation of the cyclic AMP (cAMP)/
protein kinase A signaling pathway drives cAMP response
element (CRE)-dependent MIE enhancer/promoter activation
in quiescently infected NT2 cells, thus exposing a potential
mode of regulating HCMV reactivation [19]. Whether these
mechanisms also regulate CMV infection in ES cells remains
unknown.
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the virus attaches to the (mammalian) host cell surface via
interaction between an envelope component and a cellular
molecule that serves as a receptor. After attachment, the virus
must cross the plasma membrane during a phase of its life cycle
known as penetration. The viral particle is very large, and no
infectious core particle has ever been observed in the nucleus; this
suggests that the virus is disassembled prior to nuclear entry.
Finally, viral DNA, or a DNA-protein complex, enters the nucleus.
MCMV genes are expressed in 3 sequential phases: immediate-
early, early, and late [20].
In this work, we investigated the susceptibility of mouse ES cells
to MCMV by comparing each step of the infection process (e.g.,
attachment, entry, trafficking, nuclear entry, and promoter
activity) between the most susceptible murine cells, mouse
embryonic fibroblasts (MEFs) and ES cells. We found that ES
cell susceptibility is inhibited in a multi-step manner. Additionally,
we have shown that induced pluripotent stem (iPS) cells, like ES
cells, are MCMV-resistant. We describe novel characteristics of
pluripotent stem cells (ES or iPS) and their response to CMV
infection.
Results
Establishment of ES cell lines
C57BL/6 blastocysts obtained by mating MCMV IE promoter-
lacZ transgenic mice with C57BL/6 mice were cultured in ES/
fetal calf serum (FCS) medium. Eight ES cell lines were established
after the successful growth of inner cell masses. Using previously
described methods, we confirmed that the cell lines contained a
portion of the MCMV IE promoter-lacZ (407 bp) [21]. One of
these cell lines was used for all subsequent experiments, along with
an IE promoter-negative cell line. Pluripotent differentiation
ability was confirmed in the ES T-1 cells by intraperitoneally
injecting them into young adult C57BL/6 mice and verifying the
formation of teratomas. The resulting tumor masses consisted of
both undifferentiated and differentiated cells. The differentiated
cells (e.g., epithelial cells, neural cells, chondrocytes, striated
muscle cells, and digestive gland cells) were observed in all 3
embryonic germ layers, as previously described [4]. Cell marker
activity was compared between ES cells and mouse embryonic
fibroblasts (MEFs). Unlike MEFs (Figure 1A–D), ES cells had
alkaline phosphatase activity (Figure 1E) and expressed SOX2
(Figure 1F), Nanog2 (Figure 1G), and OCT3/4 (Figure 1H).
ES cell resistance to MCMV infection
We evaluated the susceptibility of ES cells to MCMV by
comparing the infection rate of ES cells and MEFs after exposure
to MCMV. Both cell types were infected with MCMV (RM4503,
derived from the K181 strain) at a multiplicity of infection (MOI)
of 1 (determined on MEF). The infected cells first exhibited green
fluorescence protein (GFP) fluorescence at 3 days post-infection
(dpi), with the intensity increasing by 5 dpi in MEF (Figure 2A).
The cytopathic effect, which indicates the beginning of lytic cell
death, was observed in MEF at 3 dpi, whereas ES cells were rarely
GFP-positive and exhibited little cytopathic effect even after 5 dpi
(Figure 2A). We evaluated viral titer over time by comparing
values in MEF and ES cells at MOIs of both 1 and 10 (Figure 2B).
At 5 dpi, MEFs yielded 10
4 to 10
5 times more progeny virus than
ES cells at both MOIs (P,0.001). Flow cytometry, using the IE1
antigen-specific monoclonal antibody (mAb) N2 [22], was used to
evaluate the proportions of cells infected at each time point. At 3
dpi, 90.6% and 89.3% of MEF were IE1-positive when infected at
MOIs of 1 and 10, respectively. In ES cells infected at the same
MOIs, only 0.73% and 6.87% of cells were IE1-positive by day 3
(P,0.001) (Figure 2C). This suggests that ES cells have
considerable resistance to CMV.
To analyze the effect of MCMV concentration on ES cells, the
numbers of IE1-positive cells were measured after infection at
different MOIs (1, 10, 100) at 24 hours post-infection (hpi). There
were more IE1-positive cells after infection at an MOI of 10 than
at an MOI of 1. However, the proportions of IE1-positive cells
were similar after infection at MOIs of 10 and 100 (P.0.05: not
significant). Thus, while susceptibility to MCMV seems to be
concentration-dependent, ES cells reach MCMV saturation at an
MOI of 10 (Figure 2D). Immunocytochemistry showed that, at 4
hpi at an MOI of 10, MEF cultures had many IE1-positive cells,
while ES cultures had almost none (Figure 2E). This strongly
suggests that the 2 cell types differ in susceptibility prior to the IE
phase.
To analyze when ES inhibits MCMV infections (e.g., pre- or
post-transcription), real-time RT-PCR was used to quantify the
MIE RNA produced by the MCMV (Smith strain) at 3 and 6 hpi
after infection at MOIs of 1 and 10. Each sample was normalized
to concomitantly measured 18S rRNA values. At 3 hpi at MOIs of
1 and 10, MIE RNA production was 218.2 and 27.9 times higher,
Figure 1. Establishment of ES cell lines. Unlike MEF (A-D), ES cells
had alkaline phosphatase activity (E) and expressed SOX2 (F), Nanog2
(G), and OCT3/4 (H).
doi:10.1371/journal.pone.0017492.g001
Susceptibility of CMV to Embryonic Stem Cells
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17492Susceptibility of CMV to Embryonic Stem Cells
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17492respectively, in MEFs than in ES cells (P,0.01). MIE RNA
production in MEFs was significantly lower at 6 hpi than at 3 hpi
(P,0.05) (Figure 2F). This suggests that the 2 cell types differ in
susceptibility at the point of transcription.
Transfected/integrated MCMV IE promoter activity
Expression of the IE gene is highly dependent on cellular
transcription factors that bind to the DNA, including the enhancer
sequence, of the IE promoter [23]. We examined activation of the
integrated MCMV IE promoter in ES cells and MEFs derived
from MCMV IE promoter-lacZ transgenic mice. Transgenic ES
cell cultures contained no 5-bromo-4-chloro-3-indoyl-b-D-galac-
topyranoside (X-Gal)-positive cells, but the MEF cultures did
(Figure 3A). A galactosidase enzyme assay was used to measure b-
galactosidase (b-gal) activity. In ES cells, as in the negative
controls, no activity was detected; MEFs showed 7.9 mU/mL b-gal
activity (P,0.001) (Figure 3B). A similar pattern was previously
reported elsewhere [4], and these results are consistent with our
observations of infectious activity in both cell types.
A growing number of reports indicate that transient transfection
promoters and integrated promoters elicit different expression
patterns [24]. Therefore, we also investigated MCMV IE
promoter activity using the transient transfection method. As
MEFs are not easily transfected, we used immortalized mouse
embryonic fibroblast cells (NIH3T3) to achieve efficient transfec-
tion. Attractene Transfection Reagent was used to transfect
NIH3T3 and ES cells, which were subjected to flow cytometry
24 h post-transfection. Enhanced GFP (EGFP) expression under
control of the elongation factor-1a (EF-1a)/HTLV composite
promoter was also analyzed, and these values were used to
normalize data collected from ES and NIH3T3 cells. After
transfection with the MCMV IE promoter, NIH3T3 cultures had
a much higher percentage than ES cultures of GFP-positive cells
(26.8% vs. 5.2%) (P,0.001) (Figure 3C). After transfection with
the EF-1a promoter, 18.2% of NIH3T3 and 8.8% of ES cells were
GFP-positive (P,0.001). Once MCMV IE promoter activity was
normalized using EF-1a/HTLV values, ES cells were found to
have significantly less (1.7-fold) activity than NIH3T3 cells
(P,0.05) (Figure 3D). These results confirmed previous reports
that the MCMV IE promoter plays an important role in MCMV
infection in ES cells [4].
There are a variety of mechanisms whereby ES cells may silence
the MCMV IE promoter. One of these involves chromatin
structure, which plays an important role in regulating gene
expression. For instance, TSA, a histone deacetylase inhibitor,
reactivates HCMV major immediate-early regulatory region-
dependent transcription [17], while forskolin (FSK), an adenylyl
cyclase activator, greatly alleviates MIE enhancer/promoter
silencing by stimulating the cAMP pathway in quiescently infected
NT2 cells [19]. Therefore, we examined the influence of histone
modification and stimulation of the cAMP pathway on the
transfected MCMV IE promoter in ES cells. FSK (50 mM) and
TSA (100 ng/mL) were added to the culture 4 hours after ES cells
were transfected with a plasmid containing the MCMV IE
promoter. This led to a significant increase in the number of GFP-
positive cells and the intensity of GFP fluorescence, compared to
cultures treated with FSK/TSA (Figure 3E). Thus, FSK and TSA
synergistically activate the MCMV IE promoter in ES cells
(P,0.001) (Figure 3F).
Effects of FSK and TSA in MCMV-infected ES cells
As previously described, stimulating the cAMP pathway with
FSK greatly alleviates MIE enhancer/promoter silencing in
quiescently infected NT2 cells [19]. Thus, we examined whether
cAMP stimulation influences ES cell susceptibility to MCMV. As a
control, MEFs were deprived of serum for 16 h prior to infection.
ES cells and MEFs were infected with MCMV at an MOI of 1.
After 2 hours, 5, 20, or 50 mM FSK was added to each culture
(Figure 4A). Both immunocytochemistry and flow cytometry
indicated that FSK increased the percentage of IE1-positive cells
in MEF cultures in a concentration-dependent manner (from
9.16% in untreated cultures to 52.1% in cultures treated with
50 mM FSK) (P,0.001) (Figures 4A and 4B). In ES cells, on the
other hand, there was very little response to FSK stimulation (from
0.64% IE-positive cells in untreated cultures to 0.80% in cultures
treated with 50 mM FSK) (Figures 4A and 4B).
FSK stimulation activates CRE-dependent transcription
through the signaling-mediated phosphorylation of Ser133 in the
cAMP response element binding protein (CREB) [25,26]. By
measuring levels of phosphor-Ser133 CREB using a western blot
assay, it was possible to determine whether ES cells responded to
FSK stimulation. After treatment with FSK, CREB was
maximally phosphorylated at 15 min, but levels were reduced by
90 minutes, before returning to pre-stimulus levels by 180 minutes
post-stimulus (Figure 4C).
ES cultures infected with MCMV at an MOI of 1 were treated
with 4 different concentrations of TSA (Figure 4D, left) and
sodium butylate (SB) (Figure 4D, middle). The percentage of IE1-
positive cells was measured at 24 hpi and increased in
concentration-dependent response to TSA and SB (P,0.05).
Furthermore, when 100 ng/mL TSA and 50 mM FSK were
added simultaneously to ES cells infected with MCMV at an MOI
of 1, they worked synergistically to increase the percentage of IE1-
positive cells to 3.4% (P,0.05) (Figure 4D, right). ES cultures
infected with MCMV at an MOI of 10 were then treated with SB
(5 mM) or TSA (100 ng/mL), leading to 5.2% (P,0.05) and 7.7%
(P,0.01) increases in IE1-positive cells, respectively. However, we
observed the strongest response when 100 ng/mL TSA and
50 mM FSK were added simultaneously; their synergistic effects
led to an 11.5% increase in IE1-positive cells (P,0.01) (Figure 4E).
TSA and FSK treatment did not confer full permissiveness to
MCMV in ES cells, such that they behaved like MEFs. This raised
the possibility that ES cells might have other MCMV resistance
mechanisms.
Effects of the elongation factor-1a promoter in ES cells
infected with recombinant MCMV
Using the adenovirus vector transfection system, Kawabata
et al. found that the EF-1a promoter is more efficient than the
Rous sarcoma virus promoter, the CMV promoter, and the
Figure 2. Resistance to MCMV in ES cells. (A) Differences in GFP expression in MEF and ES cells at 3 and 5 dpi with MCMV (RM4503). (B) The time
course of MCMV virus (Smith strain) titer in MEF and ES cells infected at MOIs of 1 and 10. Each P-value was calculated between MEF and ES at an MOI
of 1 or 10 of the same days post-infection (dpi). (C) Differences in the proportions of IE1-positive cells in MEF and ES cultures infected at MOIs of 1 and
10. Each P-value was calculated between MEF and ES at an MOI of 1 or 10 of the same dpi. (D) Comparison of infection levels at different MOI (1, 10,
100) at 24 hpi. ES cells infected at MOIs of 10 and 100 had similar proportions of IE1-positive cells (P.0.05: n.s.). (E) IE-positive cells during the
immediate-early phase of infection in MEF and ES cells at 4 hpi. (F) MIE RNA levels in MEF and ES cells at 3 and 6 hpi. All presented experiments were
performed at least 3 times, and data are given as the mean6SD. * P,0.05, ** P,0.01, *** P,0.001, n.s.: not significant, t-test.
doi:10.1371/journal.pone.0017492.g002
Susceptibility of CMV to Embryonic Stem Cells
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17492Susceptibility of CMV to Embryonic Stem Cells
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17492b-actin promoter/CMV enhancer, in mouse ES cells [27]. After
confirming EF-1a promoter activity in ES cells (Figure 3C), we
used the Amaxa electroporation transfection system to improve
transfection efficiency in ES cells and MEFs. GFP-positive cells
under the control of the EF-1a promoter accounted for as much as
46.9% of ES cultures, while only 15.8% of MEFs were GFP-
positive (P,0.001) (Figures 5A and 5B). This indicated that ES
cells possess the intrinsic transcription factors necessary to activate
the EF-1a promoter.
Next, we generated a recombinant virus to express EGFP under
control of the EF-1a promoter (EF-1a recombinant MCMV). In
MEFs infected with recombinant virus, GFP activity was quite
high (Figure 5C) and occurred in an MOI-dependent manner
(Figure 5D). In contrast, ES cells were resistant to the recombinant
MCMV. Even at an MOI of 10, there were few GFP-positive ES
cells (Figure 5C), and the total proportion of GFP-positive cells was
much lower in ES than in MEF cultures at MOIs of 1 (P,0.05)
and 10 (P,0.001) (Figure 5D).
Centrifugation of MCMV onto ES cells enhances
infectivity
We used centrifugation and polyethylene glycol (PEG) treat-
ments to determine whether MCMV resistance in ES cells is
mediated at the adsorption or entry steps. Centrifugation is
thought to enhance the infectivity of HCMV by increasing
adsorption [28]. Enveloped viruses reach the cytoplasm by
numerous mechanisms, including fusion with the plasma mem-
brane and endocytosis followed by fusion with endosomal
membranes [29,30]. PEG chemically induces fusion by dehydrat-
ing the surfaces of juxtaposed membranes [31] and essentially
bypasses normal entry processes by inducing fusion with the
plasma membrane. In this way, PEG can force the entry of
otherwise entry-defective herpesviruses when adsorbed onto the
cell surface [32]. ES cells were inoculated with EF-1a recombinant
MCMV at an MOI of 50, with or without centrifugation, and then
subjected to a brief treatment with 44% PEG. Centrifugation
significantly (3.9-fold) increased the proportion of GFP-positive
cells (7.6%) in ES cultures (P,0.05) (Figure 6A and 6B). PEG
treatment without prior centrifugation had little effect on MCMV
susceptibility. However, PEG treatment with prior centrifugation
increased the proportion of GFP-positive cells more significantly
(9.8%) (P,0.01) (Figures 6A and 6B). MEF cultures treated with
both centrifugation and PEG had 90.0% GFP-positive cells (data
not shown). Although it is not clear whether ES cells internalize
MCMV via fusion at the plasma membrane or endocytosis, these
results suggest that infection was blocked at one or more post-entry
stages of infection, and that this blockage could not be overcome
with PEG treatment with centrifugation.
Multi-step inhibitory regulation of MCMV infection
We next compared the amounts of MCMV DNA at each step
of the infection process (binding, cell entry, nucleus entry) in ES
cells (values standardized by b-actin) and MEFs at 2 different
MOIs. MCMV was absorbed into ES and MEF at 4uC for 1 hour.
The cells were washed 3 times with cold PBS. Viral DNA was
extracted from a portion of these cells so the amount of MCMV
during the binding process could be measured. The remaining
cells were incubated at 37uC for 2 h so the virus could undergo cell
entry. Virions that did not penetrate cells were removed by
EDTA-trypsin, while the internalized viral DNA was quantified by
real-time PCR. Finally, we collected the nuclear and cytoplasmic
fractions using previously-described protocols [33]. Viral DNA
was extracted from each fraction to determine the numbers of
MCMV particles associated with nuclear entry. MCMV DNA
levels in MEFs and ES cells were standardized to b actin.
Cumulatively, our results indicate that ES cells exhibit multi-step
inhibition. In ES cells infected at MOIs of 1 and 10, MCMV DNA
levels at the binding stage were 53.2% and 51.3% lower,
respectively, than they were in MEFs (P,0.05) (Figures 7A and
7B). There was an even greater discrepancy between ES cells and
MEFs at the entry point, when MCMV DNA levels were 91.2%
and 90% lower in ES cells infected at MOIs of 1 and 10,
respectively (P,0.01) (Figures 7A and 7B). At the nuclear entry
step, ES cells infected at MOIs of 1 and 10 had 95.1% and 95.0%
less MCMV DNA, respectively, than MEFs (P,0.01). Finally, the
MEF cytoplasm contained about twice as much remnant MCMV
DNA as the ES cell cytoplasm, at MOIs of both 1 and 10
(Figure 7A and B). Semi-quantitative PCR also showed that ES
cells contained significantly less MCMV DNA in their nuclei than
MEFs did, at MOIs of both 1 and 10 (Figure 7C).
Visualization of the MCMV genome in ES cells using in
situ hybridization
We used in situ hybridization (ISH) to confirm that ES cells
contained less MCMV DNA at each stage of the infection process
(Figure 7). The probe used for DNA in situ hybridization was made
from a BAC library containing the MCMV DNA genome,
pSM3fr, as previously described [34]. MEFs and ES cells were
infected with MCMV at MOIs of 1 and 10. At 2 hpi, each cell type
was fixed with 4% paraformaldehyde and paraffin-sectioned.
MCMV DNA was immunostained with peroxidized GFP
antibody and visualized either with DAB staining (brown;
Figure 8A) or by the GFP signal directly conjugated with probes
(green; Figure 8B). Neither signal was detected in the control (non-
infection) sections (Figures 8A and 8B, left panel). As the infection
concentration increased, MCMV DNA signaling increased in both
ES cells and MEFs (Figures 8A and 8B, middle and right panels).
However, there was significantly less signaling in ES cells than in
MEFs, and although most MEF signals were localized to the
nucleus, this was rarely the case in ES cells. Thus, the ISH results
confirmed the findings of our real-time PCR analyses (Figure 7).
Resistance to MCMV in iPS
Matsukage et al. reported that ES cells became more susceptible
to MCMV after undergoing differentiation [4]. However, the
susceptibility of CMV to iPS has not yet been addressed. To create
Figure 3. Comparison of transfected/integrated MCMV IE promoter activity in MEF and ES cells. (A) Results of the galactosidase enzyme
assay on transgenic ES cells and MEF. b–gal positive cells (blue). (B) b–gal activity in wild-type MEF and transgenic ES cells and MEF. Activity could
only be detected in transgenic MEF, at 7.9 mU/mL. (P,0.001) (C, D) Detection of promoter activity by flow cytometric analysis of GFP reporter
expression. (C) The percentage of GFP positive cells with MCMV IE promoter activity and EF-1a promoter activity. (D) MCMV IE promoter activity after
normalization with EGFP expression values under the control of the EF-1a promoter. There was a significant difference between ES and NIH3T3 after
normalization (P,0.05). (E, F) Examination of the influence of histone modification and stimulation of the cAMP pathway on the transfected MCMV IE
promoter in ES cells. (E) Co-treatment with FSK and TSA drastically increased the number of GFP-positive cells. (F) FSK and TSA each increase GFP
fluorescence activity when administered individually (FSK: P,0.01, TSA: P,0.01), but the strongest response was seen when they were administered
together (P,0.001). All presented experiments were performed at least 3 times, and data are given as the mean6SD. * P,0.05, ** P,0.01,
*** P,0.001, t-test.
doi:10.1371/journal.pone.0017492.g003
Susceptibility of CMV to Embryonic Stem Cells
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17492Figure 4. Response of the MCMV lytic cycle to treatment with FSK and TSA. Both (A) immunocytochemical and (B) flow cytometric analyses
showed that treatment with FSK increases the proportion of IE1-positive cells in MEF cultures in a concentration-dependent manner (P,0.001), while
only slight increases were seen in ES cells. (C) Western blot evaluating levels of phosphor-Ser 133 CREB after treatment with FSK. (D) Percentage of IE1
antigen-positive cells at 24 hpi in ES cells infected with MCMV at an MOI of 1 prior to treatment with TSA (left), sodium butylate (SB; middle), and a
combination of TSA (100 ng/mL) and FSK (0–50 mM; right). (E) Percentage of IE1-positive cells in ES cells infected with MCMV at an MOI of 10 prior to
treatment with SB (5 mM), TSA (100 ng/mL), or a combination of TSA (100 ng/mL) and FSK (50 mM). All presented experiments were performed at
least 3 times, and data are given as the mean6SD. * P,0.05. **P,0.01, *** P,0.001, t-test.
doi:10.1371/journal.pone.0017492.g004
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(OCT4, SOX2, c-Myc, Klf-4) are sufficient to reprogram somatic
cells (fibroblasts) to pluripotent stem cells that exhibit the essential
characteristics of ES cells [35].
We acquired a mouse iPS cell line established with Oct3/4,
Sox2, Klf4, and c-myc (RIKEN BioResource Center). The GFP
gene was knocked-in under the Nanog promoter, allowing
detection of GFP in undifferentiated cells [36]. When infected at
an MOI of 1, iPS and ES cultures had similar levels of IE1-positive
cells (0.85% and 1.02%, respectively), both of which were lower
than the levels observed in MEFs (21.1%) (P,0.01) (Figure 9B).
When infected at an MOI of 10, iPS cultures had a higher
proportion of IE1-positive cells (7.27%) than did ES cultures
(2.17%) (P,0.001), both of which were significantly lower than the
levels observed in MEFs (47.2%) (P,0.001) (Figures 9A and 9B).
Interestingly, the majority of IE1- and Nanog-positive cells in iPS
cultures co-localized (data not shown), indicating that the
susceptibility of iPS is independent of differentiation.
After 3 hpi, we performed ISH to observe MCMV DNA signals
in MEF, iPS, and ES cells. ISH signaling peaked in MEF cultures,
was intermediate in iPS cultures, and was weakest in ES cultures
(Figure 9C), confirming the results of our immunocytochemical
analyses (Figure 9A). Thus, while iPS and ES cells are both more
resistant to MCMV than MEFs, iPS appears to be more
susceptible than ES cells to MCMV.
Analysis of factors thought to confer resistance to MCMV
in pluripotent cells
We investigated the role of various factors thought to affect each
step of the MCMV infection process. When binding to the cell, the
virus engaged cell-surface heparan sulfate (HS), a relatively
conserved feature of the herpesvirus entry pathway [37]. Average
Figure 5. Effects of the elongation factor-1a promoter in ES cells infected with recombinant MCMV. (A) GFP-positive cells in ES and MEF
cultures after transfection via electroporation (green: GFP; blue: DAPI) at 24 hours post-transfection. (B) ES cultures had nearly 3 times as many GFP-
positive cells (46.9%) as MEF cultures (15.8%) at 24 hours post-transfection (P,0.001). (C) Recombinant MCMV was constructed to express an EGFP
gene insert under control of EF-1a promoter. GFP positive cells were barely detectable in ES cells at 24 hpi after infection at an MOI of 10 (green: GFP,
blue: DAPI). (D) The proportion of GFP-positive cells was significantly higher in MEFs than in ES cells infected at MOIs of 1 (P,0.05) and 10 (P,0.001).
All presented experiments were performed at least 3 times, and data are given as the mean6SD. * P,0.05, **P,0.01, *** P,0.001, t-test.
doi:10.1371/journal.pone.0017492.g005
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and iPS than in MEFs (P,0.05) (Figure 10A). Additionally, when
MCMV was pretreated with heparin prior to infection, infectivity
was significantly reduced in MEFs (data not shown). Cells such as
NIH3T3, which are treated with the anti-b1 integrin-neutralizing
antibody (clone DE9), exhibit significant (. 80%) reductions in
MCMV infectivity, suggesting that MCMV primarily uses a b1
integrin-specific entry pathway [38]. The average mean fluores-
cence intensity of b1 integrin per cell is 1.8-fold lower in iPS and
3.0-fold lower in ES cultures than in MEFs (P,0.01) (Figure 10B).
Figure 7. Comparison of MCMV infection inhibition at each stage of the infection process in MEF and ES cells. The amount of MCMV
DNA was quantified at the binding and entry stages and in the nucleus and cytoplasm of MEF and ES cells infected with MCMV at MOIs of (A) 1 and
(B) 10. (C) Results from semi-quantitative PCR used to measure the amount of MCMV DNA in the nuclei of MEF and ES cells. All presented experiments
were performed at least 3 times, and data are given as the mean6SD. * P,0.05, ** P,0.01, t-test.
doi:10.1371/journal.pone.0017492.g007
Figure 6. Effects of polyethylene glycol and centrifugation on EF-1a-promoter recombinant MCMV infection in ES cells. (A) GFP-
positive cells in ES cultures treated with 44% PEG, centrifugation + PBS, or centrifugation +44% PEG after infection with EF-1a recombinant MCMV at
an MOI of 50. (B) Flow cytometry was used to verify the proportion of GFP-positive cells in each of the infection treatments. All presented
experiments were performed at least 3 times, and data are given as the mean6SD. * P,0.05, ** P,0.01, t-test.
doi:10.1371/journal.pone.0017492.g006
Susceptibility of CMV to Embryonic Stem Cells
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17492During the initial phase of HCMV infection, the virus requires
an intact network of vimentin intermediate filaments, which
appear to facilitate capsid trafficking and/or docking to the
nuclear envelope [39]. To investigate whether vimentin is also
important in MCMV infections, we treated MEFs with acrylam-
ide, which chemically disrupts the vimentin network, prior to
infecting them with EF-1a recombinant MCMV at an MOI of 10.
At 4 hpi, we measured the average fluorescence intensity in each
cell and found that disruption of the vimentin network reduced
MCMV entry in a concentration-dependent manner (Figure 10C).
Western blotting and immunocytochemical analysis revealed that
per-cell expression of vimentin was significantly lower in iPS and
ES cells than in MEFs (Figures 10D and 10E).
The precise mechanisms by which CMV enters the nucleus
after penetrating the cell are not yet understood, though it is
known that it passes through nuclear pores [20]. Importin b
mediates the process by which the herpes simplex virus (HSV)
capsid docks at the nuclear pore complex (NPC), after which the
viral genome is rapidly released into the nucleoplasm. Normally,
the 153-kb HSV genome is imported by passive diffusion, but this
process can be blocked by treatment with wheat germ agglutinin
(WGA), which blocks nuclear pores by binding to nucleoporins
containing N-acetyl-D-glucosamine (GlcNAc) residues [40,41,42].
MEFs were pretreated with Alexa Fluor 594-conjugated WGA
(Invitrogen-Molecular probe, Carisbad, CA) that was transfected
into the cells using the Chariot protein delivery system (Active
Motif, Carisbad, CA). WGA was allowed to couple with the
Chariot compound for 30 min at room temperature to form
complexes that were incubated for 1 h with MEFs suspended in
serum-free culture medium. To eliminate surface-bound WGA,
cells were treated with 0.1 M GlcNAc for 10 min, according to
Raub’s methods [43]. The WGA-treated MEFs were then infected
with MCMV at an MOI of 10. WGA nuclear pore blockage
inhibited MCMV infection in a concentration-dependent manner
(P,0.001) (Figure 10F), indicating that the number of NPCs may
influence susceptibility to MCMV. Finally, the number of NPCs
was measured using mAb mAb414, which recognizes 4 nucleo-
porins [40]. Confocal images showed that the density of nuclear
Figure 8. Visualization of the MCMV genome by in situ hybridization in MEF and ES cells. To confirm the results of the DNA quantification
experiments, in situ hybridization was used to visualize the MCMV genome in MEF and ES cells infected with MCMV at MOIs of 1 and 10. The DNA was
visualized by (A) immunostaining with DAB (brown) or by a (B) GFP signal (green).
doi:10.1371/journal.pone.0017492.g008
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(P,0.001) (Figures 10G and 10H).
Next we induced differentiation of ES cells to compare the
susceptibility of ES cells and differentiated cells to MCMV. ES cells
on nonadherent bacterial dishes formed cellular aggregates
(embryoid bodies) during growth in suspension with retinoic acid
for 8 days. Embryoid bodies were dissociated and plated onto
coated dishes in differentiation medium without leukemia inhibi-
tory factor (LIF). After several passages, differentiated cells and ES
cells were infected with EF-1a recombinant MCMV at an MOI of
10 and incubated for 24 hr. Differentiated cells exhibited a
significantly greater proportion of GFP-positive cells than did ES
cells (Figure 11A). Even at 6 hpi (prior to the onset of MCMV DNA
synthesis), the proportion of GFP-positive cells after infection with
EF-1a recombinant MCMV at MOI of 10 was significantly higher
in differentiated cells (30.4%) than in ES cells (1.2%) (P,0.001)
(Figure 11B). We performed ISH to observe MCMV DNA signals
in ES and differentiated cells at 3 hpi (MOI of 10). The number of
ISH signals is significantly higher in differentiated cells than in ES
cells (Figure 11C). These results indicate that differentiated cells are
more susceptibleto MCMV becausethe MCMVgenome canenter
the nucleus more efficiently than in ES cells. Next, we compared
several factors (heparan sulfate, b1 integrin, vimentin, nuclear
pores) between ES cells and differentiated cells. Flow cytometry
showed that average mean HS fluorescence intensity per cell was
8.1-fold greater in differentiated cells than in ES cells (P,0.001)
(Figure 11D). The average mean fluorescence intensity of b1
integrin per cell was 2.1-fold greater in differentiated cells than in
EScells (P,0.001)(Figure11E).Western blottingrevealedthat per-
cell expression of vimentin was significantly higher in differentiated
cells than in ES cells (Figure 11F). Confocal imaging showed that
nuclear pore density was significantly higher in differentiated cells
than in ES cells (P,0.001) (Figures 11G and 11H).
Discussion
Previously, little was known about the susceptibility of
embryonic stem cells to CMV infection. Gonczol et al. reported
that infected human embryonic carcinoma cells did not express
viral antigens or produce infectious virus [5]. NT2 cells, their
differentiated derivatives, and MRC-5 fibroblasts take up the virus
in a similar manner; at just 1 hpi, a significant fraction of applied
virus is found in the nucleus of each cell type [15]. Human NT2
have long been recognized as a useful model in which to study the
regulatory mechanisms behind MIE enhancer/promoter silencing
during quiescent HCMV infection [5,13,14]. In human embry-
onic carcinoma cells, the MIE promoter of HCMV is activated by
physiological levels of retinoic acid [44]. Treatment with TSA, a
histone deacetylase (HDAC) inhibitor, rendered NT2 cells
transiently permissive to HCMV, suggesting that HDACs play
an important role in the repression of viral replication [18].
Treatment with FSK, an adenylyl cyclase activator, stimulates the
cAMP signaling pathway, thereby alleviating MIE enhancer/
promoter silencing in quiescently infected NT2 neuronal precur-
sors. When TSA and FSK are administered simultaneously, they
synergistically activate the HCMV lytic cycle. Thus, it appears that
stimulation of the cAMP/protein kinase A signaling pathway
drives CRE-dependent MIE enhancer/promoter activation in
quiescently infected cells; this suggests one potential mode of
regulation in HCMV reactivation [19].
In the current study, results of the plaque assay (Figure 2B) and
IE1 protein and mRNA expression analyses (Figures 2C, 2E, and
2F) indicated that ES cells were more resistant than MEFs to
MCMV, at the level of virus production. These differences seem to
be a result of variations at the transcriptional or pre-transcriptional
level. Since the activity of the CMV promoter in NT2 has already
been the subject of intense study, we focused on the activity of the
Figure 9. Comparison of MCMV resistance in MEF, iPS, and ES cells. (A) Results from immunocytochemical analyses visualizing MCMV IE1-
positive cells (red) in the 3 cell cultures after infection with MCMV at an MOI of 10. (B) Flow cytometry was used to confirm that iPS and ES both had
lower numbers of IE1-positive cells than MEF, when infected at MOIs of 1 (P,0.01) and 10 (P,0.001). At an MOI of 10, iPS cells showed higher
expression than ES cells of IE1 (7.27% vs. 2.17%) (P,0.001). (C) Results from in situ hybridization showing that MCMV signaling in all 3 cultures was
proportional to the amount of IE1-positive cell expression. All presented experiments were performed at least 3 times, and data are given as the
mean6SD. ** P,0.01, *** P,0.001, t-test.
doi:10.1371/journal.pone.0017492.g009
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promoter was detected 2 weeks after induction of differentiation,
and was predominantly observed in glial cells [4]. Here, we
confirmed that the integrated MCMV IE promoter was activated
in transgenic MEFs, but not in ES cells (Figures 3A and B). These
results correlate with actual infectious behavior, suggesting that
non-permissiveness of ES cells may depend on IE promoter
activity. Thus, we hypothesized that ES may not have enough
transcription factors to activate the MCMV IE promoter, or that
remodeling of the chromatin associated with the IE promoter may
play a pivotal role in its activation. Ishiguro et al. reported that
transiently transfected DNA was rapidly assembled into a
chromatinized structure in 3T3 cells, suggesting that transcription
of reporter genes was at least partially repressed by chromatin
organization [45]. Here, we found that integrated and transiently
transfected MCMV IE promoters are activated differently. Our
results showed that the transiently transfected MCMV IE
promoter/enhancer has some activity in ES cells, although the
MCMV IE promoter/enhancer had less activity in ES cells than in
NIH3T3 cells (Figures 3C and 3D). These results indicated that
ES cells contained transcriptional factors for MCMV IE promoter
activation. Several reports have suggested that ES cells possess
CMV promoter activity, which is compatible with our transiently
transfected IE promoter results [46,47,48].
We found that TSA and FSK treatments significantly increased
the activity of the transiently transfected MCMV IE promoter
(Figure 3E and F). The integrated MCMV IE promoter responded
poorly and significantly differently to TSA and FSK treatment
than the transiently transfected promoter (data not shown). This
likely stems from differences in promoter modification, which
affect behavior [24]. Mehta et al. observed that HCMV promoter
silencing is dependent on the site of transgene integration. Further,
they found that the silenced CMV promoter interacts in vivo with
methyl CpG binding protein 2 (MeCP2), a recruiter of HDACs,
and histone (H3K9) methyl transferase. Histone methylation
strongly correlates with the reporter expression [49]. Therefore,
poor response to TSA and FSK stimulation may indicate that
methyl CpG and histone methylation are important factors for
silencing the integrated MCMV IE promoter in ES cells.
Unexpectedly, despite up-regulation of CREB phosphorylation,
MCMV-infected ES cells exhibited a minimal responded to high-
concentration FSK stimulation (Figure 4A and 4B). However, we
did confirm a previous report [19] that FSK and TSA work
synergistically to alleviate some, but not all, MCMV silencing
(Figure 4C). Furthermore, ES cells infected with EF-1a recombi-
nant MCMV showed very little GFP activity despite the fact that
the EF-1a promoter is active in ES cells (Figure 5). Centrifugation
significantly (3.9-fold) increased the proportion of GFP-positive
cells in ES cultures when infected with EF-1a recombinant
MCMV (Figure 6A). These results led us hypothesize that ES cells
may be susceptible to MCMV infection during pre-transcription,
when the virus attaches to and enters cells, and traffics to and
enters the nucleus. A comparison of MCMV DNA levels in MEF
and ES cells clearly showed that ES exerted multi-step inhibition
that reduced MCMV DNA throughout the infection process
(Figure 7). In situ hybridization revealed that MCMV DNA mostly
localized to the nuclei of MEFs, whereas ES cells rarely had signals
in this region (Figure 8). Thus, we concluded that the first barrier
of resistance to MCMV infection in ES cells is a reduction of
MCMV genome entry into the nucleus.
Like all herpesviruses, CMV replicates in the nucleus and
requires active transfer of virions from the cell membrane to the
nuclear envelope at the start of infection. CMV initiates infection
via a tethering interaction between virions and cell-surface
heparan sulfate proteoglycans [37]. ES cells bind approximately
half as much MCMV as MEF does, although centrifugation
increased susceptibility of ES cells to MCMV adsorption by 3.9-
fold (Figure 6B). Additionally, ES cells have approximately 2.5-fold
less HS per cell than MEFs do (Figure 9A). Nairn et al. reported
that HS synthesis was enhanced 5- and 8-fold following the
transition from mouse embryonic stem cell to embryoid bodies
and extraembryonic endodermal cells, respectively [50]. The
differentiation process may increase the amount of HS on the cell
surface, while dedifferentiation from MEF to iPS may have the
reverse effect.
After virions attach to heparan sulfate proteoglycans at the cell
surface [37], they engage one or more receptor(s), including the
integrin heterodimers a2b1, a6b1, and avb3 [38,51,52], the
platelet-derived growth factor-a receptor (PDGFRa) [53,54], and
the epidermal growth factor receptor, whose role in HCMV entry
is still debated [51]. In MCMV infection, the only identified entry
receptor is b1 integrin [38]. In our experiment, ES cells had about
3-fold less b1 integrin per cell than did MEFs (Figure 10B),
indicating that b1 integrin expression levels may control the rate of
entry of MCMV into cells. We also investigated other receptor
candidates, such as PDGFRa [53]. FCM analysis showed
PDGFRa expression was low in both iPS and ES cells, and
PDGFRa expression was not correlated to higher MCMV
susceptibility. Furthermore, use of a neutralizing antibody to
block PDGFRa did not decrease susceptibility to MCMV (data
not shown). Based on these results, we concluded that PDGFRa
does not play an important role in MCMV inhibition in ES cells.
It is also possible that MCMV uses different entry pathways in
different cell types, as has been reported for different strains of
HCMV infections [55,56,57]. In HCMV, the gH/gL/pUL (128–
131A) complex is essential for infections of endothelial, epithelial,
and dendritic cells, but is not needed for infection of fibroblasts
and neuronal cells. HCMV gH/gL complexes are thought to play
a role in promoting fusion of the viral envelope and cellular
membranes, and probably act in concert with gB, potentially
binding integrin receptors [38,52,55,58]. Like HCMV, MCMV
(Smith strain) infects many cell types, including fibroblasts,
epithelial cells, endothelial cells, macrophages, and dendritic cells
[59]. Mouse ES cells have shown resistance to both the Smith
strain and the K181-derived RM4503 strain. As far as we know,
differences in MCMV strains do not affect their ability to infect ES
Figure 10. Analysis of factors thought to confer resistance to MCMV in pluripotent cells. ES cells, iPS cells, and MEF were immunostained
with (A) heparan sulfate antibody and (B) b1 integrin antibody. Flow cytometry showed that MEFs have 2.6 times more fluorescence intensity per cell
than iPS and ES cells after staining with heparan sulfate antibody (P,0.05), and 1.8 and 3.0 times more fluorescence intensity per cell than iPS and ES
cells, respectively, after staining with b1 integrin antibody (P,0.01). (C) Effects of acrylamide treatment on MCMV susceptibility shown as the average
mean fluorescence intensity per cell at 4 hpi in MEF infected with EF recombinant MCMV (P,0.05, P,0.01 vs control). (D) Western blot showing
vimentin expression in MEF, iPS, and ES cells. (E) Immunocytochemical analyses of vimentin signals in MEF, iPS, and ES cells. (F) Proportion of GFP-
positive cells in MEF cultures infected with MCMV (EF-1a recombinant MCMV) at an MOI of 10 and treated with WGA to block nuclear pores (P,0.001
vs control). (G) Confocal images reveal the nuclear pore density in MEF, iPS, and ES cells. (H) Densitometric analysis showed that the density of nuclear
pores was higher in MEF than in iPS or ES cells (P,0.001). All presented experiments were performed at least 3 times, and data are given as the
mean6SD. * P,0.05, ** P,0.01, *** P,0.001, t-test.
doi:10.1371/journal.pone.0017492.g010
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endocytosis via an energy-dependent, pH-sensitive pathway.
MCMV uses 2 different pathways (fusion or endocytosis) to enter
fibroblasts [60]. Although different gH/gL complexes may direct
the virus to different cell types, it is not yet clear how the virus
differentially uses one complex or the other. Future studies should
focus on clarifying whether MCMV, like HCMV, uses an
alternative gH/gL complex comparable to the gH/gL/pUL
(128-131A) complex of HCMV. A combination of centrifugation
and PEG treatment did not make ES cells fully permissive, like
MEF. This suggests that MCMV was blocked at least one post-
entry stage of infection.
Disruptions of the vimentin network greatly diminish HCMV
entry into the cell nucleus. Because viral particles remain in the
cytoplasm longer in vimentin-negative than in vimentin-positive
cells, it has been hypothesized that viral genomes enter the nucleus
via vimentin association with integrins at the cell surface, with
endosomes and microtubules in the cytoplasm, and with the
lamina and matrix in the nucleus [39]. This suggestion is
supported by reports that ES cells express less vimentin than do
differentiated cells [61,62,63]. Using both immunocytochemistry
and western blotting, we confirmed that ES cells and iPS expressed
less vimentin than did MEFs (Figure 10D). Chemical disruption of
the vimentin network with acrylamide severely reduced entry of
MCMV in a concentration-dependent manner (Figure 10C).
Ivaska et al. reported that the efficient recycling of b1 integrins to
the plasma membrane requires the PKCe-regulated phosphory-
lation of amino-terminal sites on vimentin. This process is also
required for efficient migration on a b1 integrin substrate [64].
When vimentin expression is lacking, virions may not be capable
of efficiently transferring viral capsids to the nucleus. Indeed,
failure to transport particles to the nucleus and achieve nuclear
genome deposition results in reductions in the cytoplasmic viral
DNA levels of endothelial cells [65]. Lower levels of vimentin
expression in ES cells and iPS appear to play an important role in
MCMV infection by inhibiting capsid trafficking and/or docking
to the nuclear envelope.
The nuclear pore is an integral part of the nuclear membrane of
all eukaryotic cells. It permits the diffusion of small molecules and
the active transport of larger molecules between the nucleus and
cytoplasm. The mechanism by which genomes of large DNA
viruses are translocated through the nuclear pore complex (NPC)
are poorly understood, and appear to vary by virus species [42,66].
Also poorly understood is the mechanism by which the CMV
genome enters the nucleus; it may employ mechanisms similar to
those of HSV. Yasuhara et al. showed that expression of importin-
a subtypes is strictly regulated during neural differentiation in
mouse ES cells, and that the switching of importin-a subtype
expression is critical for neural differentiation. However, both
mouse embryonic stem cells and differentiated cells constantly
express importin b [67]. Future work is needed to elucidate
whether these factors are important in CMV nuclear entry and, if
so, what role they play.
Here, we confirmed that WGA, which is transduced into cells
via the Chariot protein delivery system, inhibited MCMV
infection in a concentration-dependent manner. This indicates
that MCMV entered the CMV genome through the NPC and
suggests that the number and/or density of functional nuclear
pores may affect susceptibility to CMV by reducing the rate of
capsid docking at NPCs. ES cells and iPS have lower nuclear pore
densities than do MEFs, which supports previous findings that
nuclear pore densities are low in ES cells, and only increase after
differentiation [68]. This may explain why MCMV enters MEFs
at a 2-fold higher rate than it enters ES cells. However, there may
be additional mechanisms that also influence this pattern, and
future work is needed to investigate this possibility.
Another aspect of this study is to look at MCMV as a gene
transfer vector. Recombinant MCMV has been explored as a
potential antigen delivery vector due to its ability to target human
dendritic cells without compromising the antigen-presenting
ability of dendritic cells[69]. Additionally, MCMV undergoes an
abortive infection in human cells and is safe for use in humans
[69,70,71]. MCMV can express transgenes and can potentially
carry rather large DNA fragments since its genome is large (about
230kb) and only about 80 genes appear to be necessary for its
replication. Our study indicates that recombinant MCMV may
not be a suitable vector to introduce exogenous genes into
pluripotent stem cells. On the other hand, there is a possibility that
MCMV may introduce multiple transgenes simultaneously into
differentiated human cells. Furthermore MCMV may be used to
introduce exogenous genes such as Oct3/4, Sox2, Klf4, and c-myc
into human fibroblasts to generate human iPS. Future work is
needed to investigate this possibility.
This is the first report that the resistance of pluripotent stem
cells to CMV entry is a multi-step process. In addition to the low
rate of MCMV genome entry into the nucleus, it is also likely that
an epigenetic inhibitory mechanism represses MCMV transcrip-
tion, and that these 2 processes work together to make ES cells
highly resistant to CMV infection. There may be other
mechanisms to be revealed in the future. It is also probable that
differentiation and dedifferentiation change the factors that we
have shown to influence CMV susceptibility, including HS, b1
integrin, and vimentin expression, as well as the density of nuclear
pores. We confirmed that ES cell differentiation increased
susceptibility to MCMV and increased nuclear pore density and
the expression of heparan sulfate, b1 integrin, and vimentin
(Figure 11). These results indicate that differentiated cells are more
susceptible to MCMV because the MCMV genome can enter the
nucleus more efficiently than in ES cells. It has long been thought
that the CMV genome enters the nuclei of pluripotent stem cells in
the same manner in which it invades fibroblasts [5]. Ours is the
first report that ES and iPS permit lower levels of CMV genome
entry into the nucleus than MEFs do. This finding should help
elucidate the relationship between CMV susceptibility and the
developmental process, which may eventually lead to treatments
for reducing the occurrence of congenital anomalies caused by
CMV infection in humans.
Figure 11. Analysis of factors for MCMV susceptibility during cell differentiation. (A) More GFP-positive cells were observed in
differentiated cells than in ES cells after infection with EF-1a recombinant MCMV at an MOI of 10 at 24 hpi. (B) At 6 hpi, the proportion of GFP-positive
cells after infection with EF-1a recombinant MCMV at an MOI of 10 was significantly higher in differentiated cells (30.4%) than in ES cells (1.2%) (P,
0.001) (C) In situ hybridization was used to visualize the MCMV genome in ES and differentiated cells infected with MCMV at an MOI of 10. (D) Average
mean heparan sulfate fluorescence intensity per cell was 8.1-fold greater in differentiated cells than in ES cells (P,0.001). (E) The average mean
fluorescence intensity of b1 integrin per cell is 2.1-fold greater in differentiated cells than in ES cells (P,0.001). (F) Western blotting revealed that per-
cell expression of vimentin was significantly higher in differentiated cells than in ES cells. (G) Confocal imaging showed that the nuclear pore density
is significantly higher in differentiated cells than in ES cells. (H) Densitometric analysis confirmed the results shown in (G) (P,0.001). All presented
experiments were performed at least 3 times, and data are given as the mean6SD. ***P,0.001, t-test.
doi:10.1371/journal.pone.0017492.g011
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Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Hamamatsu University School of Medicine
(Permit Number: 2007089). All surgery was performed under
sodium pentobarbital anesthesia, and all efforts were made to
minimize suffering.
Mice
C57BL/6 mice were obtained from SLC Japan (Hamamatsu,
Japan). Transgenic mouse lines that expressed the lacZ gene under
transcriptional control of the MCMV major IE promoter 1
(MCMV IE promoter-lacZ transgenic) were described previously
[21,72].
Establishment of ES Cell Lines and ES/iPS culture
ES cell lines were established as described by Matsukage et al.
[4]. C57BL/6 female mice were mated with C57BL/6 or
homozygous MCMV IE promoter-lacZ transgenic males, and
the presence of vaginal plugs was verified the following morning.
On gestational day (GD) 3.5, blastocysts were collected from the
uterine cavity by flushing with Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FCS. Blastocysts were
cultured on MEFs, which had been treated with mitomycin C, in
35-mm plastic dishes with ES/FCS medium at 37uCi na
humidified atmosphere of 95% air and 5% CO2. The ES/FCS
medium consisted of DMEM supplemented with 15% FCS, 1000
U LIF (Chemicon International, Temecula, CA), and 10
-4 M2 -
mercaptoethanol (2-ME; Sigma Chemical, St. Louis, MO),
nonessential amino acids (Invitrogen Corp., Carlsbad, CA),
sodium pyruvate (Invitrogen), and penicillin. The recovered
blastocysts were washed with CaH- and MgH-free PBS and
treated with 0.01% trypsin and 1 mM EDTA at 37uC for a few
minutes. After ES/FCS medium was added to neutralize the
trypsin, the inner cell mass (ICM) was dissociated into small
clumps by pipetting, and the clumps were seeded into a new dish
with MEF feeder cells containing ES/knockout serum replace-
ment medium (Invitrogen), which replaced the FCS with KSR. At
5–7 days after dissociation of the ICM, small round colonies were
generated in some dishes. These were trypsinized and seeded into
new 35-mm dishes. Culture medium was replaced daily.
Blastocysts hatched after 2 days of culture and attached to the
dish surface. After 5 days the ICM of the blastocysts proliferated to
form a round clump at the center of the trophoectodermal cell
sheet. Nanog-iPS (APS0001, iPS-MEF-Ng-20D-17) was obtained
from the RIKEN BRC Cell Bank (Tsukuba, Japan) and
maintained in ES cell medium.
Induction of ES cell differentiation into various cell types
For embryoid body formation (EB), ES cells were plated onto
nonadherent bacterial dishes (Greiner) in EB medium (ES medium
without LIF and only 10% FCS) and incubated for 8 days.
Medium was changed every 2 days and 5 mM retinoic acid was
added after 4 days. Embryoid bodies were dissociated and the cells
plated. Dissociated cells were maintained with EB medium for
more than 4 weeks.
Alkaline phosphatase staining
Cells were washed twice with PBS and fixed with 4%
formaldehyde (in PBS) for approximately 15 min at room
temperature. The cells were washed with PBS and incubated
with an alkaline phosphatase substrate solution for 10 min at room
temperature. After washing with PBS, the cells were photo-
graphed.
Immunocytochemistry
Immunocytochemical staining was performed as described
previously [73]. The fixed cells (ES and MEF) on dishes were
stained with anti-mouse-Nanog antibody (Reprocell, Tokyo,
Japan), anti-rabbit-SOX2 antibody (Abcam, Cambridge, UK),
anti-mouse-OCT3/4 antibody (Santa. Cruz Biotechnology, Santa
Cruz, CA, USA) and mAb N2, specific to the MCMV IE-89K-
antigen [22], and anti-mouse-vimentin (PROGEN Biotechnik
GmbH, Heidelberg). The secondary antibody (green) was Alexa
Fluor 488 goat anti-rabbit, -rat or -mouse IgG (H+L) (Molecular
probes, Invitrogen, CA, USA), incubated for 1 h. DAPI was used
to stain the cell nuclei (blue).
Virus
The Smith strain of MCMV was provided by Dr. Y.
Minamishima (Miyazaki, Japan) [74]. Recombinant MCMV
(RM4503) capable of expressing EGFP was provided by Dr.
Mocarski (Stanford University, Stanford, CA)[75]. RM4503 was
constructed to express EGFP under control of an HCMV
promoter/enhancer inserted into the MCMV ie2 gene, which
has been shown to be completely dispensable for viral growth,
latency, and pathogenesis in BALB/c mice [76].
Generation of recombinant virus
Recombinant viruses, derived from the Smith strain of wild-type
MCMV (gene accession number U68299) capable of expressing the
EGFP (Clontech, Palo Alto, CA), were used in this study.
Recombinant virus was constructed to express an EGFP gene
insert under control of EF-1a (EF-1a/HTLV composite promoter
that combines the EF-1a core promoter and the 59 untranslated
region of the Human T-cell Leukemia Virus. The EF-1a/HTLV
promoter was taken from pSELECT plasmid (InvivoGen, San
Diego, CA, USA)). EF-1a/HTLV promoter-EGFP was inserted
between 184443 and 187158 in the MCMV genome by
homologousrecombination. Thisrecombination causesthe deletion
of a 2716 nt sequence including the MCMV ie2 gene (m128;
position from 186085 to 187296), which is completely dispensable
for viral growth in cell culture as well as for growth, latency, and
pathogenesis in mice [76]. A recombinant virus was created by co-
transfection of MEFs with MCMV Smith strain genomic DNA and
a DNA fragment carrying the EF-1a/HTLV promoter-EGFP
cassette with 59-(position from 183078 to 184442) and 39-(position
from 187159 to 188573) flanking sequences using FuGENE 6
transfection reagent (Roche Diagnostics, Mannheim, Germany).
Virus infection of ES Cells and MEFs
ES cells and MEFs were incubated with MCMV for 1.5 hr at
an MOI of 1, 10, and 100 plaque-forming units per cell, washed
with Hank’s balanced salt solution (Invitrogen) 3 times, and
cultured with fresh medium. At different times after infection, the
supernatants and infected cells from 3 samples were collected. The
virus was quantified by the plaque assay method of Wentworth
and French [77] with MEFs, as reported previously [78]. Infected
cells were processed for MCMV antigen detection by fluorescent
microscopy, immunofluorescence, and flow cytometry. The
numbers of GFP-positive ES cells or MEFs after infection with
recombinant MCMV (RM4503) were counted in 10 high-power
fields on photographs using a fluorescent microscope.
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For flow cytometry, ES cells and MEF were treated as
previously described [4]. The cells were reacted in suspension
with mAb N2, specific to the MCMV IE-89K-antigen. For the
secondary labeling, phycoerythrin (PE)- or FITC-conjugated
rabbit anti-rat immunoglobulins (Dako) were used for MCMV
antigen detection. The stained cells were analyzed by flow
cytometry using an EPICS profile analyzer (Coulter, Miami, FL).
Reverse transcription-PCR (RT-PCR)
Total RNA from MEFs and ES cells was isolated at 3 hours and
6 hours after infection by using the RNeasy Mini Kit (Qiagen,
Hilden Germany) according to the manufacturer’s protocol. RNA
samples were treated with RNAse-free DNAse I for 15 min at
room temperature, and the DNAse was inactivated at 65uC for
15 min. The RNA was reverse-transcribed using oligonucleotide
primers at 50uC for 50 min, and reactions were terminated by
heating at 70uC for 15 min. The reverse-transcribed products
were treated with RNase H for 20 min at 37uC. Quantification of
the viral transcripts from genes m123 (ie1) was performed by real-
time one-step RT-PCR with the primers and probes indicated as
follows. For ie1-specific RT-PCR, probe ie1-taq1 directed against
the exon 3/4 splicing junction comprised nucleotides 59-6,338 to
6,328 on exon 4 and 59-6,205 to 6,192 on exon 3 (GenBank
accession no. L06816). Oligonucleotide 59-6,393 to 6,367 served
as forward primer ie1_taq_forw1, and oligonucleotide 59-6,139 to
6,156 served as reverse primer ie1_taq_rev1, yielding an
amplification product of 133 bp. The fluorogenic 59 nuclease
probe was 59-FAM[6-carboxy-fluorescein]-AACGCTCCT-
CACTGCAGCATGCTTG-39-TAMRA [6-carboxy-tetramethyl
rhodamine])[79]. 18S rRNA was used to normalize for variations
in RNA extraction. The 18S oligonucleotide primers were
TaqMan Gene Expression assays, Endogenous control; 18S
(mouse: Hs99999901_s1) (FAM). Assays were performed in
triplicate using a one-step protocol consisting of an initial
reverse-transcription reaction followed immediately by cDNA
amplification. All TaqMan reagents were purchased from Applied
Biosystems. RNA (2 mL) was added to 18 mL of PCR mix in each
well of a MicroAmp optical reaction plate containing 10 ml
TaqMan Fast Universal PCR Master Mix, 6.9 mL distilled water,
0.304 mL each of 50 mM ie1 forward and ie1 reverse primers,
0.492 mL of 0.26 mM FAM-labeled probe, 2 mL of a mixture of
18S forward and reverse primers, and 0.125 mLo f4 0mM 18S
rRNA-FAM-labeled probe. The samples were amplified in a
StepOnePlus realtime PCR system (Applied Biosystems) using the
following program: 1 cycle; 95uC for 20 s, 1 cycle; and 95uC for
1 s and 60uC for 20 s, 40 cycles.
Galactosidase staining and galactosidase enzyme assay
After fixation for 1 hr in 4% paraformaldehyde (in 0.1 M PBS)
at 4uC and washing with PBS, the IE promoter-lacZ transgenic ES
or MEF cells were stained for b-gal activity using the method of
Mercer et al. with X-Gal. The IE promoter-lacZ transgenic ES
cells and transgenic MEFs and non-transgenic MEFs were fixed in
4% paraformaldehyde for 5 min and washed with PBS [80]. b-gal
activity was detected by X-Gal staining, and b-gal-positive cells
were photographed in 10 hpf. The b-galactosidase Enzyme Assay
System (Promega) was used according to the manufacturer’s
protocol.
Construction of plasmids and transfection
Plasmids were constructed from the plasmid vector pEGFP-C1
(Clontech). After the deletion of the HCMV enhancer/promoter
sequence and multiple cloning sites from pEGFP-C1, PCR-
amplified MCMV MIE enhancer/promoter of ie1 and ie3
(MCMV-MIE pro1) or EF-1a/HTLV composite promoter were
cloned into the MluI and AseI/NheI sites of pEGFP-C1,
respectively. MCMV-MIE pro1 was selected using PCR with
primers specific for the ie1 gene yielding 1338 bp. EF-1a/HTLV
composite promoter combines the elongation factor 1a core
promoter and the 59 untranslated region of the Human T-cell
Leukemia Virus. EF-1a/HTLV promoter was taken from the
pSELECT plasmid (InvivoGen, San Diego, CA, USA). At the 59
and 39positions of each promoter cassette, 2 sequences with
homology to the MCMV gene-containing fragment (from 183078
to 184442) to the 59 site and another fragment (from 187159 to
188573) to the 39site were inserted. Attractene Transfection
Reagent (Qiagen, Hilden Germany) was used to transfect the
plasmids into ES cells and MEFs. Transfection into ES cells and
MEFs was performed using a Nucleofector electroporator (Amaxa
Biosystems, Germany) according to the manufacturer’s recom-
mended protocol.
Drug treatment
Stock solutions of trichostatin A (1 mg/mL), sodium butylate
(1400 mM), FSK (10 mM) (Sigma, St. Louis, MO) were prepared
in dimethyl sulfoxide. Immediately before addition, these were
diluted to the desired concentrations in DMEM.
Western blotting
CREB protein and phosphorylated CREB protein were
detected using rabbit antibody specific to CREB (Upstate Cell
Signaling, Virginia) and phosphorylated CREB (Affinity BioR-
eagents, Colorado). Sample loads were standardized by detecting
b-actin using mouse mAb specific to b-actin (Sigma). The blots
were incubated with biotin-conjugated secondary antibody
(Nichirei, Japan) followed by horseradish peroxidase-conjugated
avidin-biotin reaction. Immunoreactive bands were visualized
using enhanced chemiluminescence substrate (Amersham Phar-
macia Biotech, NZ).
Centrifugal and PEG enhancement of infection
Culture dishes were centrifuged at 600 g for 2 h at room
temperature and then moved to 37uC for 1 h. The cells were
washed twice with PBS and treated with polyethylene glycol or
returned to 37uC. PEG 6000 (Nakarai Tesuque Corporation,
Kyoto, Japan) was prepared as a 60% (wt/wt) solution in PBS and
diluted with warm PBS to 44%. Cells were treated with diluted
PEG for 30 s and washed immediately 5 times with warm PBS.
The treated cells were infected with EF-1a recombinant MCMV
at an MOI of 50. After 24 hpi, the number of GFP-expressing cells
was quantified.
Cell collection and fractionation
Cell fractionation was performed according to Wang et al. ’s
protocol [33]. Cells were harvested by trypsinization and collected
in 15-ml conical tubes on ice, washed 3 times with cold PBS,
transferred to microfuge tubes, and pelleted at 4000 rpm for 3 min
in a refrigerated centrifuge. Cell pellets were resuspended in 1 mL
RSB (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl2),
incubated for 3 min on ice, followed by centrifugation at 4uC.
The volume of the swelled cell pellet was estimated and
resuspended by slow pipetting with 4 volumes of lysis buffer
RSBG40 [10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl2,
10% glycerol, 0.5% Nonidet P-40, 0.5 mM dithiothreitol (DTT),
and 100 U/mL rRNasin (Promega, WI)]. Nuclei were pelleted by
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recovered and saved as the cytoplasmic fraction. Nuclear pellets
were resuspended in RSBG40, and one-tenth volume of detergent
[3.3% (wt/wt) sodium deoxycholate and 6.6% (vol/vol) Tween 40]
was added with slow vortexing, followed by incubation on ice for
5 min. Nuclei were again pelleted and the supernatant was pooled
with the previous cytoplasmic fraction. Nuclear pellets were
washed once more in RSBG40, collected at 10,000 rpm for 5 min,
and the resulting pellet used for nuclear DNA extraction. Cell lysis
and nuclear integrity was monitored by light microscopy following
trypan blue staining.
Quantification of viral genomes in cell
DNA was extracted with a DNeasy tissue kit (QIAGEN). Viral
genomes were quantified by real-time PCR using the SYBRH
Green PCR Master Mix (Applied Biosystems). A 2 ml aliquot of
the DNA was added as template DNA to a reaction mixture that
included the 2X SYBRH Green PCR Master Mix with 1 mMo f
each primer. A fragment of the gB gene was amplified from
mCMV virion DNA by PCR using oligonucleotides gB-forw (59-
GAAGATCCGCATGTCCTTCAG-39) and gB-rev (59-AATCC-
GTCCAACATCTTGTCG-39) [81], and primers for amplifica-
tion of a fragment of the cellular b-actin gene were forward, (59-
GACGGCCAAGTCATCACTATTG-39), reverse, (59-AGGAA-
GGCTGGAAAAGAGCC-3’). PCR was performed with the
following cycling conditions. The samples were amplified in a
StepOnePlus realtime PCR system (Applied Biosystems): 95uC for
10 min, 1 cycle; and 95uC for 15 s and 60uC for 60 s, 40 cycles.
Semiquantitative PCRs were performed under the following
conditions with using the Phusion kit (FINNZYMES, Espoo,
Finland): 1 cycle at 94uC for 30 s; 30 cycles of 10 s at 94uC, 10 s at
the corresponding annealing temperature, and 20 s at 72uC; and 1
cycle at 72uC for 5 min.
In situ hybridization
The probe for DNA in situ hybridization, pSM3fr, was made
from the MCMV DNA genome with a bacterial artificial
chromosome system by nick translation as described previously
[34]. In situ hybridization to MCMV DNA was performed as
described previously [34]. The cells were treated with RNase
(Boehringer; 100 mg/mL in PBS) for detection of viral DNA.
Nuclear pore inhibition with wheat germ agglutinin
Wheat germ agglutinin was allowed to couple with the Chariot
compound (Active Motif, Carisbad, CA) for 30 min at room
temperature to form complexes. The complexes were incubated
for 1 h with MEFs suspended in serum-free culture medium.
Successful transfection of WGA into MEFs results in blockage of
the nuclear pores. To eliminate surface-bound WGA, cells were
treated with 0.1 M GlcNAc for 10 min, according to Raub’s
methods [43].
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